Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at Citizens Jmp

Citizens Jmp began coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report issued on Monday,Benzinga reports. The brokerage set a “market outperform” rating and a $52.00 price target on the stock. Citizens Jmp’s target price would suggest a potential upside of 192.79% from the stock’s previous close.

A number of other brokerages have also recently issued reports on AVTX. HC Wainwright boosted their price objective on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Guggenheim started coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They set a “buy” rating and a $50.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. Wall Street Zen raised Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. Finally, Mizuho raised Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $44.20.

Avalo Therapeutics Price Performance

NASDAQ AVTX opened at $17.76 on Monday. Avalo Therapeutics has a twelve month low of $3.39 and a twelve month high of $20.72. The firm has a market capitalization of $404.75 million, a PE ratio of -3.10 and a beta of 0.93. The stock’s 50 day moving average is $15.54 and its 200 day moving average is $16.04.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of ($0.21) million. On average, research analysts anticipate that Avalo Therapeutics will post -19.07 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Christopher Ryan Sullivan sold 7,980 shares of the stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $17.15, for a total transaction of $136,857.00. Following the sale, the chief financial officer directly owned 17,338 shares of the company’s stock, valued at $297,346.70. This trade represents a 31.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $16.15, for a total value of $411,695.80. Following the completion of the sale, the insider owned 3,622 shares of the company’s stock, valued at $58,495.30. The trade was a 87.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 42,130 shares of company stock worth $693,225. Corporate insiders own 3.03% of the company’s stock.

Institutional Investors Weigh In On Avalo Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP purchased a new position in shares of Avalo Therapeutics in the 4th quarter worth $1,150,000. XTX Topco Ltd increased its position in Avalo Therapeutics by 190.0% during the fourth quarter. XTX Topco Ltd now owns 40,458 shares of the company’s stock valued at $735,000 after acquiring an additional 26,508 shares during the last quarter. Squadron Capital Management LLC bought a new position in Avalo Therapeutics in the fourth quarter valued at about $2,361,000. SummitTX Capital L.P. bought a new position in Avalo Therapeutics in the fourth quarter valued at about $3,557,000. Finally, Millennium Management LLC boosted its position in Avalo Therapeutics by 380.2% in the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock worth $11,985,000 after purchasing an additional 522,548 shares during the last quarter. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.